HCMBMAG-22K
MILLIPLEX® Human Cancer/ Metastasis Biomarker Panel 9-Plex
Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel
Sign In to View Organizational & Contract Pricing.
About This Item
UNSPSC Code:
12161503
NACRES:
NA.84
eCl@ss:
32161000
Product Name
MILLIPLEX® Human Cancer/ Metastasis Biomarker Panel 9-Plex, Configurable Human Cancer/Metastasis Biomarker 9-Plex Panel
species reactivity
human
manufacturer/tradename
Milliplex®
Quality Level
packaging
1 ea of
assay range
accuracy: 70-105%
standard curve range: 0,019-80 ng/mL
(TRAP5)
standard curve range: 0,048-20 ng/mL
(YKL40)
standard curve range: 0.002-10 ng/mL
(GDF15)
standard curve range: 0.007-30 ng/mL
(DKK-1)
standard curve range: 0.007-30 ng/mL
(OPG)
standard curve range: 0.036-150 ng/mL
(NSE)
standard curve range: 0.195-800 ng/mL
(Periostin)
standard curve range: 0.976-4,00 0 ng/mL
(Osteonectin (SPARC))
inter-assay cv: <16%
intra-assay cv: <10%
technique(s)
multiplexing: suitable
input
serum plasma (Cell culture, cell culture supernatants)
detection method
fluorometric (Luminex® xMAP® technology)
shipped in
wet ice
storage temp.
2-8°C
General description
The MILLIPLEX®Human Cancer/Metastasis Biomarker Panel 1 contains nine metastasis biomarkers that have also been identified in a variety of tumor types. Coupled with the Luminex® xMAP® platform in bead format, this panel enables researchers to focus on discovery with the advantage of simultaneous quantitative multiplex detection leading to speed and sensitivity.
Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.
Panel Type: Circulating Cancer
Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.
Panel Type: Circulating Cancer
Metastasis is a complex process in which tumor cells leave the primary tumor site and migrate to other parts of the body via blood and lymph vessels or by tumor invasion of surrounding tissues and organs. Breaking away from the primary tumor, cancer cells attach to and degrade extracellular matrix proteins that separate tumor from surrounding tissues to escape into the stroma. Where metastases form often depends on the primary tumor. Bone metastases, for example, tend to arise from breast, prostate and kidney tumors. This organ/tissue specificity seems to involve chemical signals from both chemokines and growth factors.
Legal Information
Luminex is a registered trademark of Luminex Corp
MILLIPLEX is a registered trademark of Merck KGaA, Darmstadt, Germany
xMAP is a registered trademark of Luminex Corp
Application
MILLIPLEX® Qualified assays undergo rigorous assay development, verification, and Quality Control testing to achieve optimal performance. Simultaneously analyze up to 9 analytes in human serum, plasma, tissue/cell culture supernatants or lysate samples.Analytes included: DKK-1, GDF-15, Neuron-specific Enolase (NSE), Osteonectin (SPARC), Osteoprotegerin (OPG), Periostin, TRAP5, TWEAK, YKL40 (CHI3L1)Assay Characteristics: Refer to kit protocol for assay cross-reactivity, sensitivity, precision, and accuracy.
Disclaimer
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
For research use only. Not for use in diagnostic procedures.Label License/Sticker for Assay Product:By opening the packaging containing this Assay Product (which contains fluorescently labeled microsphere beads authorized by Luminex Corporation) or using this Assay Product in any manner, you are consenting and agreeing to be bound by the End User Terms and Conditions and the End User License Agreement available at http://support.diasorin.com/end-user-terms-and-conditions/. If you do not agree to all of the terms and conditions, you must promptly return this Assay Product for a full refund prior to using it in any manner.
Features and Benefits
- Comprehensive Biomarker Detection: The panel includes nine key metastasis biomarkers (DKK-1, GDF-15, NSE, Osteonectin, OPG, Periostin, TRAP5, TWEAK, YKL40) relevant to various tumor types.
- Multiplex Detection Capability: Utilizes the Luminex®xMAP® platform in bead format to enable simultaneous quantitative analysis of multiple biomarkers, enhancing throughput and efficiency.
- Flexible Sample Types: Compatible with human serum, plasma, and tissue/cell culture supernatants or lysates, providing versatility in sample collection.
- Configurable Kit Design: Researchers can design their multiplex kit by selecting analytes tailored to their specific research needs.
- Facilitates Understanding of Metastatic Mechanisms: By providing insights into the biomarkers associated with metastasis, the panel aids in understanding the complex processes of tumor cell migration and organ specificity.
signalword
Danger
Hazard Classifications
Acute Tox. 3 Dermal - Acute Tox. 4 Inhalation - Acute Tox. 4 Oral - Aquatic Chronic 2 - Eye Dam. 1 - Skin Sens. 1 - STOT RE 2
target_organs
Respiratory Tract
Storage Class
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
wgk
WGK 3
Regulatory Information
新产品
This item has
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
R H Brophy et al.
Osteoarthritis and cartilage, 27(12), 1778-1789 (2019-08-21)
Emerging evidence suggests that injury to the anterior cruciate ligament (ACL) typically initiates biological changes that contribute to the development of osteoarthritis (OA). The molecular biomarkers or mediators of these biological events remain unknown. The goal of this exploratory study
Paul G Corn et al.
Clinical cancer research : an official journal of the American Association for Cancer Research, 26(5), 990-999 (2020-01-17)
Cabozantinib, an oral inhibitor of c-MET/VEGFR2 signaling, improved progression-free survival (mPFS) but not overall survival (OS) in metastatic castrate-resistant prostate cancer. We evaluated cabozantinib plus androgen deprivation therapy (ADT) in hormone-naïve metastatic prostate cancer (HNMPCa). Patients received ADT plus cabozantinib
Alison Crichton et al.
Journal of neurotrauma, 38(8), 1151-1163 (2019-12-28)
Despite many children experiencing fatigue after childhood brain injury, little is known about the predictors of this complaint. To date, traditional indices of traumatic brain injury (TBI) severity have not predicted reliably persisting fatigue (up to three years post-injury). This
Related Content
Cancer biomarker detection through MILLIPLEX® multiplex cancer assays can accelerate studies of tumorigenic processes helping advance cancer research.
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service